Novel, very stable ruthenium and osmium containing terminal phosphinidene complexes [(eta(6)-Ar)(L)M=Mes*] (Ar=benzene, p-cymene; L=PR(3), CO, and RNC) have been prepared by dehydrohalogenation of novel [(eta(6)-Ar)MX(2)(PH(2)Mes*)] complexes in the presence of a stabilizing ligand. Xray crystal structures are reported for [(eta(6)-C(6)H(6))(PPh(3))Rud=PMes*] (9) and [(eta(6)-pCy)(PPh(3))Os=PMes*] (4). Dehydrohalogenation in the absence of a stabilizing ligand resulted in the new P-spiroannulated Ru(2)P(2)-ring structure 16. Dehydrohalogenation in the presence of but-2-yne gave a novel phosphaallyl complex [(eta(6)-Ar)Ru(eta(3)-R(2)PC(Me)CHMe)] 26, for which an X-ray crystal structure is reported. The mechanism by which 16 and 26 are obtained is presumed to involve the intermediate formation of the 16-electron (eta(6)-benzene)Rud=PMes* phosphinidene complex.
Stable, crystalline iridium-complexed phosphinidenes, Cp*(L)IrdPR, are readily synthesized by (a) the reaction of Cp*(L)IrCl 2 (2, L) PPh 3) with LiPHMes* and (b) dehydrohalogenation of Cp*(PH 2 R)IrCl 2 (5, R) Mes*, Is, Mes) with in situ capturing of transient Cp*Irt PR (4) with phosphines, phosphites, arsines, isocyanides, and carbon monoxide (L). Cp*Irt PR eluded direct detection. The X-ray crystal structures are reported for Cp*(PPh 3)IrdPMes* (3) and Cp*(CO)IrdPMes* (15). The more congested 3 has an E configuration for its IrdP bond, whereas 15 is obtained in its Z form. The 31 P NMR chemical shifts and 2 J PP coupling constants are diagnostic for the E and Z forms. More shielded phosphinidene resonances and larger coupling constants are typical for the E isomers. These iridium-complexed phosphinidenes react with gem-diiodides to form phosphaalkenes, but not with carbonyl groups.
A capillary electrophoresis detection technique for (small) peptides is presented, i.e. quenched phosphorescence, a method that is generally applicable and does not require chemical derivatization. For this purpose, a novel phosphorophore, 1-bromo-4-naphthalenesulfonic acid (BrNS), was synthesized. BrNS has sufficient water solubility and provides strong phosphorescence at room temperature over a wide pH range. The detection is based on the dynamic quenching of the BrNS phosphorescence background signal by electron transfer from the amino group of the peptides at pH 9.5-10. For the di- and tripeptides Val-Tyr-Val, Val-Gly-Gly, Ala-Ser, Gly-Asn, Gly-Ala, and Gly-Tyr, detection limits in the range of 5-20 microg/L were obtained. The novel technique is even a good alternative for the (limited) group of peptides containing tyrosine and, thus, exhibiting native fluorescence as well as strong UV absorption: using Gly-Tyr, Val-Tyr-Val, methionine enkephalin, and human angiotensin II as test compounds, quenched phosphorescence detection was found to compare favorably with absorption detection at 190- and 266-nm laser-induced fluorescence detection, as performed with a recently developed, small-size, quadrupled Nd:YAG laser.
Dimer im Kristall, trimer in Lösung ist ortho‐Phenylenzink, das jetzt aus der analogen Quecksilberverbindung und Zink synthetisiert werden konnte. In Lösung liegt das im Bild gezeigte Gleichgewicht weit auf der rechten Seite. Das Dimer kristallisiert wahrscheinlich wegen günstigerer Packungseffekte.
The reaction of 10-phenyl-10-germa-9-silatriptycene (1b) with phenyllithium in THF/HMPA produced 9,10-diphenyl-10-germa-9-silatriptycene (1a), which had hitherto not been accessible. The reaction proceeds by attack of the phenyl anion on 1b via the intermediate silicate anion 7, which was identified by 29 Si NMR spectroscopy. The structure of 1a was confirmed by X-ray crystallography. As a model reaction, the attack of phenyllithium on triphenylsilane (8) and diphenylsilane ( 14) was investigated by 29 Si NMR spectroscopy, revealing the formation of a number of novel hydridosilicates analogous to 7.
Activation parameters have been determined for the 2-vinylphosphirane−3-phospholene rearrangement
in the cycloheptane annellated series 7 → 8. For the thermal reaction, the mean activation parameters (ΔH
⧧ =
125 ± 5 kJ mol-1 and ΔS
⧧ = −1 ± 14 J K-1 mol-1) are as expected for a biradicaloid character of the
transition structure. In the presence of Cu(I) as a catalyst, the activation parameters for this conversion (ΔH
⧧
= 80.2 ± 3 kJ mol-1 and ΔS
⧧ = −100 ± 7 J K-1 mol-1) are strikingly different and more in line with a
concerted pathway.
The properties of the 16‐electron phosphinidene complex [CpRIrPR] were investigated experimentally and theoretically. Density functional theory calculations show a preferred bent geometry for the model complex [CpIrPH], in contrast to the linear structure of [CpIrNH]. Dimerization to give [{CpIrPH}2] and ligand addition to afford [Cp(L)IrPH] (L=PH3, CO) were calculated to give compounds that were energetically highly favorable, but which differed from the related imido complexes. Transient 16‐electron phosphinidene complex [Cp*IrPAr] could not be detected experimentally. Dehydrohalogenation of [Cp*IrCl2(PH2Ar)] in CH2Cl2 at low temperatures resulted in the novel fused‐ring systems 17 (Ar=Mes*) and 20 (Ar=Mes), with dimeric [{Cp*IrPAr}2] being the likely intermediate. Intramolecular CH bond activation induced by steric factors is considered to be the driving force for the irreversible formation of 17 and 20. ONIOM calculations suggest this arises because of the large steric congestion in [{Cp*IrPAr}2], which forces it toward a more reactive planar structure that is apt to rearrange.
o-Phenylenemagnesium (1) was used to
prepare the first structurally characterized intramolecularly
coordinated diindacycle:
9,10-dihydro-9,10-bis[2,6-bis((dimethylamino)methyl)phenyl]-9,10-diindaanthracene (3).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.